Serum Sclerostin Levels Negatively Correlate with Parathyroid Hormone Levels and Free Estrogen Index in Postmenopausal Women
Serum Sclerostin Levels Negatively Correlate with Parathyroid Hormone Levels and Free Estrogen Index in Postmenopausal Women
复制标题
DOI：
10.1210/jc.2009-2283
复制
发表时间：
2010-04-01
影响因子：
5.8
通讯作者：
Lorenzo, Joseph A.
中科院分区：
文献类型：
--
作者：
Mirza, Faryal S.;Padhi, I. Desmond;Lorenzo, Joseph A.
背景：硬化蛋白是骨形成的负调节因子。目的：本研究的目的是比较绝经前和绝经后妇女血清硬化蛋白水平，并评估其与雌激素、促甲状腺激素、骨转换和骨量的关系。设计、环境和参与者：我们对健康的社区绝经前和绝经后妇女进行了横断面观察研究。干预措施：无干预措施。主要结局指标：我们比较了绝经前和绝经后妇女血清硬化蛋白水平，并将硬化蛋白水平与女性性激素、促钙化激素、骨转换标志物和骨密度相关。结果：绝经前妇女年龄26.8岁，绝经后妇女年龄56.8岁。与绝经前妇女相比，绝经后妇女的雌二醇（30 +/- 23比10 +/- 4 pg/ml， P < 0.001）、雌酮（61 +/- 24比29 +/- 10 pg/ml， P < 0.001）和游离雌激素指数（FEI）（6 +/- 4比3 +/- 2 pmol/nmol， P = 0.008）和所有部位的骨密度显著降低，PTH、25-羟基或1,25-二羟基维生素D水平无显著差异。绝经后妇女血清硬化蛋白水平明显升高（1.16 +/- 0.38 ng/ml vs. 0.48 +/- 0.15 ng/ml; P < 0.001）。由于大多数绝经前妇女服用口服避孕药，因此随后的分析仅限于绝经后妇女。在本组中，硬化蛋白与FEI、硬化蛋白与PTH呈显著负相关。通过多元回归分析，发现FEI （β = - 0.629; P = 0.002）和PTH （β = -0.554; P = 0.004）是绝经后妇女硬化蛋白水平的独立预测因子。结论：我们的研究结果表明绝经后妇女血清硬化蛋白水平受雌激素和甲状旁腺激素共同调节。这些发现需要在更大规模的前瞻性研究中进一步探索。[J] .中华内分泌杂志（英文版）
Context: Sclerostin is a negative regulator of bone formation. Objective: The aim of the study was to compare serum sclerostin levels in premenopausal and postmenopausal women and evaluate its relationship to estrogen, TH, bone turnover, and bone mass.Design, Setting, and Participants: We conducted a cross-sectional observational study of healthy community-dwelling pre- and postmenopausal women.Intervention(s): There were no interventions.Main Outcome Measure(s): We compared serum sclerostin levels in pre- and postmenopausal women and correlated sclerostin levels with female sex hormones, calciotropic hormones, bone turnover markers, and bone mineral density.Results: Premenopausal women were 26.8 yr old, and postmenopausal women were 56.8 yr old. Postmenopausal women had lower values for estradiol (30 +/- 23 vs. 10 +/- 4 pg/ml; P < 0.001), estrone (61 +/- 24 vs. 29 +/- 10 pg/ml; P < 0.001), and free estrogen index (FEI) (6 +/- 4 vs. 3 +/- 2 pmol/nmol; P = 0.008) and significantly lower bone mineral density at all sites compared to premenopausal women, with no significant differences in levels of PTH, 25-hydroxy or 1,25-dihydroxy vitamin D levels. Postmenopausal women had significantly higher serum sclerostin levels (1.16 +/- 0.38 ng/ml vs. 0.48 +/- 0.15 ng/ml; P < 0.001). Because most of the premenopausal women were on oral contraceptives, subsequent analyses were limited to postmenopausal women. There were significant negative correlations between sclerostin and FEI and sclerostin and PTH in this group. Using multiple regression analysis, both FEI (beta = - 0.629; P = 0.002) and PTH (beta = -0.554; P = 0.004) were found to be independent predictors of sclerostin levels in postmenopausal women.Conclusions: Our findings suggest that serum sclerostin levels are regulated by both estrogens and PTH in postmenopausal women. These findings need to be explored further in larger prospective studies. (J Clin Endocrinol Metab 95: 1991-1997, 2010)